Literature DB >> 33944995

Okur-Chung neurodevelopmental syndrome-linked CK2α variants have reduced kinase activity.

I Dominguez1, J M Cruz-Gamero2, V Corasolla3, N Dacher2, S Rangasamy4, A Urbani5,6, V Narayanan4, H Rebholz7,8,9,10.   

Abstract

The Okur-Chung neurodevelopmental syndrome, or OCNDS, is a newly discovered rare neurodevelopmental disorder. It is characterized by developmental delay, intellectual disability, behavioral problems (hyperactivity, repetitive movements and social interaction deficits), hypotonia, epilepsy and language/verbalization deficits. OCNDS is linked to de novo mutations in CSNK2A1, that lead to missense or deletion/truncating variants in the encoded protein, the protein kinase CK2α. Eighteen different missense CK2α mutations have been identified to date; however, no biochemical or cell biological studies have yet been performed to clarify the functional impact of such mutations. Here, we show that 15 different missense CK2α mutations lead to varying degrees of loss of kinase activity as recombinant purified proteins and when mutants are ectopically expressed in mammalian cells. We further detect changes in the phosphoproteome of three patient-derived fibroblast lines and show that the subcellular localization of CK2α is altered for some of the OCNDS-linked variants and in patient-derived fibroblasts. Our data argue that reduced kinase activity and abnormal localization of CK2α may underlie the OCNDS phenotype.

Entities:  

Year:  2021        PMID: 33944995     DOI: 10.1007/s00439-021-02280-5

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  67 in total

1.  Predominance of CK2α over CK2α' in the mammalian brain.

Authors:  Ilaria Ceglia; Marc Flajolet; Heike Rebholz
Journal:  Mol Cell Biochem       Date:  2011-07-15       Impact factor: 3.396

2.  Construction of a physical map of an autism susceptibility region in 7q32.3-q33.

Authors:  K S Beyer; S M Klauck; S Wiemann; A Poustka
Journal:  Gene       Date:  2001-07-11       Impact factor: 3.688

3.  Prevalence and significance of the commonest phosphorylated motifs in the human proteome: a global analysis.

Authors:  Luca Cesaro; Lorenzo A Pinna
Journal:  Cell Mol Life Sci       Date:  2020-02-12       Impact factor: 9.261

4.  Okur-Chung neurodevelopmental syndrome: Eight additional cases with implications on phenotype and genotype expansion.

Authors:  A T G Chiu; S L C Pei; C C Y Mak; G K C Leung; M H C Yu; S L Lee; M Vreeburg; R Pfundt; I van der Burgt; T Kleefstra; T M-T Frederic; S Nambot; L Faivre; A-L Bruel; M Rossi; B Isidor; S Küry; B Cogne; T Besnard; M Willems; M R F Reijnders; B H Y Chung
Journal:  Clin Genet       Date:  2018-02-13       Impact factor: 4.438

5.  The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta.

Authors:  Ashley C Bibby; David W Litchfield
Journal:  Int J Biol Sci       Date:  2005-04-01       Impact factor: 6.580

6.  Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins.

Authors:  Jantine Ac Broek; Paul C Guest; Hassan Rahmoune; Sabine Bahn
Journal:  Mol Autism       Date:  2014-07-30       Impact factor: 7.509

7.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

8.  Effects of CK2β subunit down-regulation on Akt signalling in HK-2 renal cells.

Authors:  Estefania Alcaraz; Jordi Vilardell; Christian Borgo; Eduard Sarró; Maria Plana; Oriano Marin; Lorenzo A Pinna; José R Bayascas; Anna Meseguer; Mauro Salvi; Emilio Itarte; Maria Ruzzene
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

9.  Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.

Authors:  Anthony Kong; Daniel Rea; Samreen Ahmed; J Thaddeus Beck; Rafael López López; Laura Biganzoli; Anne C Armstrong; Massimo Aglietta; Emilio Alba; Mario Campone; Shu-Fang Hsu Schmitz; Caroline Lefebvre; Mikhail Akimov; Soo-Chin Lee
Journal:  Oncotarget       Date:  2016-06-21

10.  Refining the clinical phenotype of Okur-Chung neurodevelopmental syndrome.

Authors:  Moe Akahira-Azuma; Yoshinori Tsurusaki; Yumi Enomoto; Jun Mitsui; Kenji Kurosawa
Journal:  Hum Genome Var       Date:  2018-03-29
View more
  4 in total

1.  Mechanism of CK2 Inhibition by a Ruthenium-Based Polyoxometalate.

Authors:  Simone Fabbian; Gabriele Giachin; Massimo Bellanda; Christian Borgo; Maria Ruzzene; Giacomo Spuri; Ambra Campofelice; Laura Veneziano; Marcella Bonchio; Mauro Carraro; Roberto Battistutta
Journal:  Front Mol Biosci       Date:  2022-06-02

Review 2.  Comparing Two Neurodevelopmental Disorders Linked to CK2: Okur-Chung Neurodevelopmental Syndrome and Poirier-Bienvenu Neurodevelopmental Syndrome-Two Sides of the Same Coin?

Authors:  Demetra Ballardin; Jose M Cruz-Gamero; Thierry Bienvenu; Heike Rebholz
Journal:  Front Mol Biosci       Date:  2022-05-26

3.  Structural and Enzymological Evidence for an Altered Substrate Specificity in Okur-Chung Neurodevelopmental Syndrome Mutant CK2αLys198Arg.

Authors:  Christian Werner; Alexander Gast; Dirk Lindenblatt; Anna Nickelsen; Karsten Niefind; Joachim Jose; Jennifer Hochscherf
Journal:  Front Mol Biosci       Date:  2022-04-04

4.  The Okur-Chung Neurodevelopmental Syndrome Mutation CK2K198R Leads to a Rewiring of Kinase Specificity.

Authors:  Danielle M Caefer; Nhat Q Phan; Jennifer C Liddle; Jeremy L Balsbaugh; Joseph P O'Shea; Anastasios V Tzingounis; Daniel Schwartz
Journal:  Front Mol Biosci       Date:  2022-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.